| Identification | Back Directory | [Name]
7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]- | [CAS]
477600-73-0 | [Synonyms]
N-((3R,4R)
Tofacitinib-10
Tofacitib impurity TZ4
Tasocitinib Intermediate
-1-Benzyl-4-methylpiperidin-3-yl)
N-((3R,4R)-1-BENZYL-4-METHYLPIPERIDIN-3-YL)-N-METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-
N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
N-Methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
(3R, 4R)-(1-benzyl-4-methyl-piperidin-3-yl) -methyl- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -amine
1H-Pyrrolo[2,3-d]pyriMidin-4-aMine,N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-
7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-
7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]- ISO 9001：2015 REACH
Tofacitinib impurity 6/N-Methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine | [Molecular Formula]
C20H25N5 | [MDL Number]
MFCD16877475 | [MOL File]
477600-73-0.mol | [Molecular Weight]
335.45 |
| Chemical Properties | Back Directory | [Melting point ]
67-69℃ | [density ]
1.205±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [pka]
13.36±0.50(Predicted) | [InChI]
InChI=1S/C20H25N5/c1-15-9-11-25(12-16-6-4-3-5-7-16)13-18(15)24(2)20-17-8-10-21-19(17)22-14-23-20/h3-8,10,14-15,18H,9,11-13H2,1-2H3,(H,21,22,23)/t15-,18+/m1/s1 | [InChIKey]
UMWNXPTXDOVDFE-QAPCUYQASA-N | [SMILES]
C1=NC(N(C)[C@@H]2[C@H](C)CCN(CC3=CC=CC=C3)C2)=C2C=CNC2=N1 |
| Hazard Information | Back Directory | [Uses]
N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine is an important pharmaceutical intermediate used for the synthesis of tofacitinib. Tofacitinib is a Janus kinase (JAK) inhibitor drug used to treat rheumatoid arthritis and psoriatic arthritis. | [Synthesis]
N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine is prepared by the reaction of 4-chloropyrrolopyrimidine and (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride. The specific synthesis steps are as follows:
The reaction flask is added to sodium hydroxide (10.0g, 250mmol), water and dissolved, make 10% of the solution, adding acetone to another reaction bottle 80g, the toluene sulfonyl chloride (38.13g, 200mmol), after stirring to dissolve, then adding 4-chloro pyrrolo pyrimidine (15.36g, 100mmol), stirring mixing, cooling to 0 °C the following, dropping sodium hydroxide solution, the temperature is controlled at 5 °C the following, completion of the dropping, heating, to control the temperature to 20-30 °C stirring within the range of the reaction, to the reaction end after TLC monitoring, filtering, to get the product into the reaction bottle, adding water 200 ml, (3R, 4R)-cis-1-benzyl-4-methyl-3-methylamino-piperidine dihydrochloride (21.33g, 105mmol), stirring to dissolve, then adding potassium carbonate (82.93g, 600mmol), stirring, heating 95 °C, TLC monitoring to the reaction end of the, cooling to 45-55°C, by adding acetonitrile, preserving heat and stirring 1 hour, cooling to room temperature, crystallization, filtration, washing, the wet articles in added in the reaction bottle, adding dimethyl sulfoxide 250 ml, by adding 50% sodium hydroxide solution to 250 ml, stirring and heating 95 °C, TLC monitoring to the reaction end rear, layered, water extraction once with dimethyl sulfoxide, merger dimethyl asian sulphone level, cooling to 75-85°C, water slowly under stirring, the stirring cooling to room temperature, filtering, washing, 50% ethanol washing, filtering, drying, be [(3R, 4R) - 1 benzyl-4-methyl-piperidin-3-yl]-methyl-(7H-pyrrolo [2,3-d] pyrimidin-4-yl)-amine 25.83g, yield 77.0%, optical purity 99.8% (HPLC method).
![N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine synthesis](/NewsImg/2024-01-11/6384057056171848491778669.png "N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine synthesis")
|
|
|